PropertyValue
?:abstract
  • The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients. A newly developed vaccine against SARS-Cov-2 has been reported to induce the production of neutralizing antibodies in young volunteers. However, the vaccine has shown limited benefit in the elderly, suggesting an age-dependent immune response. As a result, exploring new applications of existing medications could potentially provide valuable treatments for COVID-19. N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2. This review offers a thorough analysis of NAC and discusses its potential use for treatment of COVID-19.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.2147/tcrm.s273700
?:journal
  • Ther_Clin_Risk_Manag
?:license
  • cc-by-nc
?:pdf_json_files
  • document_parses/pdf_json/e29898beb3f3c934a297a068340b76e4cf53b97d.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7649937.xml.json
?:pmcid
?:pmid
?:pmid
  • 33177829.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • N-Acetylcysteine to Combat COVID-19: An Evidence Review
?:type
?:year
  • 2020-11-02

Metadata

Anon_0  
expand all